GeoVax Labs Inc (GOVX) Quote

Uncle Sam $343 million and $45 million funding . Shorts running for the hills still. Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon trading Tuesday amid news that the US government plans to fund a Phase 2b study of the company's next-generation COVID-19 vaccine.

Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.

Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.




GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:

As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.
As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients. ClinicalTrials.gov Identifier: NCT04639466.
About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Wish I knew but I like the ride up.

What leaked?

GOVX new 52 week low

GOVX new 52 week low

GOVX new 52 week lo

$GOVX bottom bio recent r/s 2.48M float with $3.54 cash per share and warrants at $6.21 CEO and CFO bought at these levels this month + 13G of 9.99% from 14/02/24

''GeoVax to Present at the 2024 BIO CEO & Investor Conference at February 26, 2024, 4:15 pm ET'' pic.twitter.com/8sXy5x4gpa— STOCKS Gambino (@StocksGambino) February 26, 2024

GOVX new 52 week low

GOVX

GOVX new 52 week low

pure scam

GOVX new week low

GOVX: effective Jan. 31,2024 a one for 15 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

they've been trying for weeks to pump up the price before the R/S, but it didn't fool anyone.

Interesting to see the SP here when the dust settles after the R/S.

Will average down when it hits .05 again

GOVX new 52 week low

GOVX new 52 week low

GOVX new 52=week low

GOVX new 52 week low

Merry Christmas $$$$$$$$

Are you surprised?
This is a R/S dump stock.
The only ones that benefit from holding this stock are the crafty/lucky peeps or the insiders.
How long before the next R/S makes this stock look attractive to investors that don't know any better than to look past the hype?

GOVX new 52 week low

just went to ZERO BORROW,no shares to short,never been optionable

end of july,last 3 years,ran big

Going up river $$$$$$ FISH ON $$$$$

is this trash still listed? unbelievable

Lol

Three months with no fundamental change, the elastic on the jock strap is worn out.

Hold on to your jock straps $$$$$$$$

.6902 intraday gap fill this week and looking at Late Feb for next opportunity imo

I have no information on these important questions.

How soon could they do it? Do they have the money for it?

Develop the clinical/health applications for their patents, monetize these patents.

What are they expected todo next?

You failed to read the News...

it is hopeless, P&D on no news, will crash as always. Obsolete trash

Analysts calling for a minimum of $3 and a maximum of $8!!! LET'S GET IT!

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on GeoVax Labs and set a price target of $8.00.

Currently, the analyst consensus on GeoVax Labs is a Moderate Buy with an average price target of $5.50

In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.

Really nice here.

https://www.marketscreener.com/amp/quote/stock/GEOVAX-LABS-INC-112977270/news/GeoVax-Receives-Notice-of-Allowance-for-Zika-Vaccine-Patent-42811350/

Ya I've heard that, and they're over 400 different strains of the flu too...I mean Covid, you know...variants...lol

Might want to check your information. The Sudan Ebola virus is not the same as the Zaire Ebola virus. There are biological differences and as such the vaccines aren't interchangeable.

GOVX

In the works? The Ebola vaccine was already developed back in 2019'

is this trash still listed????

Ebola is spreading, they have the vax in the works...nuff said

GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
October 26 2022 - 09:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.
Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others.

Wednesday, November 9, 2022, 4:30 PM EST

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13733113

Webcast: GeoVax Earnings Webcast

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through February 9, 2023. A telephonic replay of the call can be accessed by calling 877-660-6853 (domestic) or 201-612-7415 (international), using access code 13733113. The telephonic replay will be available until November 23, 2022.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Media Relations Contact:
Gina Cestari
6 Degrees
917-797-7904
gcestari@6degreespr.com

This Company is not garbage. This Company consists of dedicated, hard-working human beings, with the goal of producing effective medicines for the healing and survival of sick humanity.

is this garbage still listed on nasdaq? Cannot believe it

Agree.

You are welcome.

I watched the conference and it appears they have a chance of becoming a profitable biotech company.

The pipeline is quite robust, imo. Their approach of activating the T Cells stands to make their platform for vaccines be very valuable and very successful, if they can commercialize and develop their pipeline. All my opinion of course.

Thanks for sharing that link.